english.prescrire.org > Prescrire International > N°187 - November 2017

n°187

November 2017

Issue Contents
Editorial

Free  Obesity drugs: too much harm, for far too long

p.255

Marketing Authorisations


Emtricitabine + tenofovir disoproxil (Truvada°) to prevent HIV transmission

p.257-259
For certain people at high risk of acquiring HIV infection

Inset. Intermittent rather than continuous daily prophylaxis

p.259

Eribulin (Halaven°) and inoperable refractory or relapsed liposarcoma

p.260-261
An option to consider, but with severe adverse effects

INN Common stem: -fovir

p.261

Tolvaptan (Jinarc°) and polycystic kidney disease

p.262
Too many adverse effects, uncertain efficacy

Asfotase alfa (Strensiq°) and hypophosphatasia

p.263-264
Increased chance of survival for very young children

Adverse Effects


Less pulmonary embolism and fewer cardiovascular events with contraceptives containing 20 micrograms of ethinylestradiol

p.265-266

Death of a child from a colchicine overdose

p.266-267

Benzodiazepines: pneumonia

p.267

Free  Nifuroxazide: serious immunoallergic reactions

p.268

Free  Levothyroxine: panic attacks

p.268

Reviews


Medical abortion in the community setting

p.269-273
The procedures and legal restrictions should be clearly explained to women

Type 2 diabetes

p.273
Don't aim for too low an HbA1c

Ischaemic stroke

p.274-275
Addition of clopidogrel to aspirin to prevent recurrence?

Outlook


The sugar lobby's crusade against dental health measures

p.276-279

Inset. The sugar lobby and cardiovascular health

p.278

Masthead


Free  Masthead

p.254

The complete contents of 
this issue of Prescrire International
are available for download by
Prescrire International subscribers.
Certain texts are also available to
non-subscribers for free download,
as indicated. 

 

Subscribe